{"id":2262,"date":"2008-01-08T15:55:53","date_gmt":"2008-01-08T14:55:53","guid":{"rendered":"http:\/\/www.ethicalquote.com\/index.php\/2008\/01\/08\/innovation-et-philanthropie-dopent-le-marche-des-vaccins\/"},"modified":"2008-01-09T16:01:41","modified_gmt":"2008-01-09T15:01:41","slug":"innovation-et-philanthropie-dopent-le-marche-des-vaccins","status":"publish","type":"post","link":"https:\/\/www.covalence.ch\/index.php\/2008\/01\/08\/innovation-et-philanthropie-dopent-le-marche-des-vaccins\/","title":{"rendered":"Innovation et philanthropie dopent le march\u00e9 des vaccins"},"content":{"rendered":"<p><a href=\"http:\/\/www.lemonde.fr\/web\/article\/0,1-0@2-3234,36-996957@51-628859,0.html\" target=\"_blank\" title=\"080109_merck_vaccines.jpg\"><img decoding=\"async\" src=\"http:\/\/www.ethicalquote.com\/newTemplate\/wp-content\/uploads\/2008\/01\/080109_merck_vaccines.jpg\" title=\"080109_merck_vaccines.jpg\" alt=\"080109_merck_vaccines.jpg\" align=\"right\" \/><\/a>En 2007, le laboratoire am\u00e9ricain Merck a supplant\u00e9 Sanofi Aventis \u00e0\u00a0 la t\u00e0\u00aate du classement mondial des producteurs de vaccins. GlaxoSmithKline (GSK), qui talonnait Sanofi, se retrouve donc num\u00e9ro trois. Sur les neuf premiers mois de 2007, Merck a r\u00e9alis\u00e9 2,13 milliards d&#8217;euros de chiffre d&#8217;affaires, son dauphin Sanofi Aventis 2,12 milliards et GSK 1,9 milliard. Gr\u00e0\u00a2ce au Gardasil, un vaccin innovant contre le cancer du col de l&#8217;ut\u00e9rus, les ventes 2007 du nouveau leader mondial devraient approcher les 3 milliards d&#8217;euros.(&#8230;) Le quatri\u00e8me facteur de croissance &#8211; et non des moindres &#8211; tient aux flux financiers nouveaux en provenance de fondations (Bill et Melinda Gates par exemple) ou de nouveaux m\u00e9canismes comme l&#8217;Iffim (Facilit\u00e9 internationale pour la vaccination) qui a mobilis\u00e9 1 milliard de dollars pour sa premi\u00e8re ann\u00e9e de fonctionnement en 2007. Ces capitaux charitables s&#8217;investissent aussi bien dans la recherche que dans des programmes de vaccinations et jouent un r\u00f4le-cl\u00e9 dans la dynamisation du secteur. Image source: AFP\/TOM MIHALEK \/ Le Monde. &gt; <a href=\"http:\/\/www.lemonde.fr\/web\/article\/0,1-0@2-3234,36-996957@51-628859,0.html\" target=\"_blank\">Continue<\/a>.<\/p>\n<p>News selected by Covalence <span class=\"LinkBlueTransMedium\">| Country: Global<\/span><span class=\"LinkBlueTransMedium\"> | Company: <\/span><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/index.php\/ethicalquote\/?value=8\">Merck &amp; Co, Sanofi Aventis, GlaxoSmithKline<\/a><span class=\"LinkBlueTransMedium\"> | <\/span>Source: <a href=\"http:\/\/www.lemonde.fr\/web\/article\/0,1-0@2-3234,36-996957@51-628859,0.html\" target=\"_blank\">Le Monde<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>En 2007, le laboratoire am\u00e9ricain Merck a supplant\u00e9 Sanofi Aventis \u00e0\u00a0 la t\u00e0\u00aate du classement mondial des producteurs de vaccins. GlaxoSmithKline (GSK), qui talonnait Sanofi, se retrouve donc num\u00e9ro trois. Sur les neuf premiers mois de 2007, Merck a r\u00e9alis\u00e9 2,13 milliards d&#8217;euros de chiffre d&#8217;affaires, son dauphin Sanofi Aventis 2,12 milliards et GSK 1,9&hellip;<\/p>\n","protected":false},"author":665,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"wds_primary_category":0,"wds_primary_post_series":0,"footnotes":""},"categories":[1],"tags":[62,40,10],"post_series":[],"class_list":["post-2262","post","type-post","status-publish","format-standard","hentry","category-news","tag-gsk","tag-merck-co","tag-sanofi-aventis","entry","no-media"],"_links":{"self":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/2262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/users\/665"}],"replies":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/comments?post=2262"}],"version-history":[{"count":0,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/2262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/media?parent=2262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/categories?post=2262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/tags?post=2262"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/post_series?post=2262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}